Another mechanism is the cleavage of BCMA by γ-secretase in myeloma cells, leading to a short extracellular structural domain of BCMA allowing direct shedding and an increase in soluble BCMA, thus binding these antigens to CAR T cells and limiting their effectiveness (72) (Figure 4). Here, TNFRSF17 is linked to plasma cell myeloma.